Qnexa

Jefferies & Company has published a research report on VIVUS (NASDAQ: VVUS) commenting on the company's Qnexa approval ahead the July 17 decision by the FDA. In the report, Jefferies wrote, "We consider heart rate (HR) elevations to be the remaining critical issue for Qnexa approval by July 17...

Dear Vivus (NASDAQ: VVUS) investors: You are paying $2.5 billion for a company with zero profits in a market space valued at only $3.5 billion annually. Yes, the FDA advisory committee recommended Qnexa be granted approval in a 20-to-2 vote, but remember that Provenge had a unanimous safety vote...

Best 1) Global Crossing (NASDAQ: GLBC): Vaulting 74.19% to $25.78 after Level 3 Communications (NASDAQ: LVLT) announced that it will acquire the company in an all-stock purchase (16 shares of Level 3 common stock for each share of Global Crossing common or preferred). 2) American Medical Systems...

The market was quiet for most of the morning but has just recently begun to come under some selling pressure. All three major indices are now sitting in negative territory. The current top 5% gainers and losers in the market are:   Best 1) McCormick & Schmick's Seafood Restaurants (NASDAQ:...

After opening slightly to the upside, the major indices have been meandering around neutral territory for most of the day. Traders are seemingly unsure as they assess the continuing rise in oil and commodities and evaluate the potential impact on the economy. Here are the five best/worst performers...

The market opened slightly to the upside this morning with the Dow Jones Industrial Average, S&P 500, and NASDAQ Composite all posting slight gains. The market is looking to build on last week's positive momentum, which saw positive economic numbers in many areas including the Jobs Report and...

Vivus (NASDAQ: VVUS) plummeted 56.98%, or $6.92, to $5.21 after the FDA rejected its weight loss drug Qnexa. VVUS’ shares gained 10.59% over the past month and 3.59% over the past week, after the FDA acknowledged that Qnexa was successful in reducing weight. Read more from Benzinga's Company news.

Shares of VIVUS Inc (NASDAQ: VVUS) soared as high as 23% in pre-market trading after the US regulators commented on its drug Qnexa. The FDA mentioned today that VVUS weight loss drug Qnexa is effective in helping obese patients shed pounds. VVUS' shares have gained 15.76% year-to-date and moved up...

Investors in biotech company Vivus Inc. (Nasdaq: VVUS) are hoping that the company's new anti-obesity drug Qnexa will be a hit in the weight loss market. Vivus President Peter Tam said that Qnexa, which is awaiting U.S. approval, could potentially generate over $1 billion in sales per year in the...